Final ALTA-1 results of brigatinib (BRG) and crizotinib (CRZ) in ALK inhibitor-naive non-small cell lung cancer (NSCLC)
Griesinger, F. Camidge, D. R. Kim, H. R. Ahn, M. J. Yang, J. C. Han, J. Y. Hochmair, M. Lee, K. H. Delmonte, A. Garcia, C. M. R.
Griesinger, F.
Camidge, D. R.
Kim, H. R.
Ahn, M. J.
Yang, J. C.
Han, J. Y.
Hochmair, M.
Lee, K. H.
Delmonte, A.
Garcia, C. M. R.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Griesinger F, Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, et al. Final ALTA-1 Results of Brigatinib (BRG) and Crizotinib (CRZ) in ALK Inhibitor-naive Non-small Cell Lung Cancer (NSCLC). Oncology Research and Treatment. 2022 Sep;45(SUPPL 2):103-4. PubMed PMID: WOS:000864724100196.